Prasugrel.
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyridine derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y(12) receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Ticlopidine
- Thiophenes
- Receptors, Purinergic P2Y12
- Rats
- Pyridines
- Purinergic P2 Receptor Antagonists
- Prodrugs
- Prasugrel Hydrochloride
- Platelet Aggregation Inhibitors
- Platelet Aggregation
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Ticlopidine
- Thiophenes
- Receptors, Purinergic P2Y12
- Rats
- Pyridines
- Purinergic P2 Receptor Antagonists
- Prodrugs
- Prasugrel Hydrochloride
- Platelet Aggregation Inhibitors
- Platelet Aggregation